Evogene Valuation
| EVGN Stock | USD 1.32 0.01 0.75% |
Today, the firm appears to be undervalued. Evogene shows a prevailing Real Value of $2.16 per share. The current price of the firm is $1.32. Our model computes the value of Evogene from reviewing the firm fundamentals such as Profit Margin of (2.25) %, shares outstanding of 8.71 M, and Current Valuation of 14.11 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Evogene's valuation include:
Price Book 4.7059 | Enterprise Value | Enterprise Value Ebitda (0.81) | Price Sales 1.8249 | Enterprise Value Revenue 2.0861 |
Undervalued
Today
Please note that Evogene's price fluctuation is abnormally volatile at this time. Calculation of the real value of Evogene is based on 3 months time horizon. Increasing Evogene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Evogene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Evogene Stock. However, Evogene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.32 | Real 2.16 | Target 4.75 | Hype 1.33 | Naive 1.4 |
The intrinsic value of Evogene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Evogene's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Evogene helps investors to forecast how Evogene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Evogene more accurately as focusing exclusively on Evogene's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Evogene's intrinsic value based on its ongoing forecasts of Evogene's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Evogene's closest peers.
Evogene Cash |
|
Evogene Valuation Trend
Knowing Evogene's actual value is paramount for traders when making sound investment determinations. Using both Evogene's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Evogene Total Value Analysis
Evogene is currently forecasted to have valuation of 14.11 M with market capitalization of 12.35 M, debt of 12.87 M, and cash on hands of 35.25 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Evogene fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
14.11 M | 12.35 M | 12.87 M | 35.25 M |
Evogene Investor Information
The company recorded a loss per share of 2.51. Evogene had not issued any dividends in recent years. The entity had 1:10 split on the 25th of July 2024. Based on the measurements of operating efficiency obtained from Evogene's historical financial statements, Evogene may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Evogene Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Evogene has an asset utilization ratio of 21.35 percent. This suggests that the Company is making $0.21 for each dollar of assets. An increasing asset utilization means that Evogene is more efficient with each dollar of assets it utilizes for everyday operations.Evogene Ownership Allocation
The market capitalization of Evogene is $12.35 Million. Roughly 94.1 percent of Evogene outstanding shares are held by general public with 0.96 (percent) owned by insiders and only 4.94 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Evogene Profitability Analysis
The company reported the previous year's revenue of 8.51 M. Net Loss for the year was (18.05 M) with profit before overhead, payroll, taxes, and interest of 2.78 M.About Evogene Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Evogene. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Evogene based exclusively on its fundamental and basic technical indicators. By analyzing Evogene's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Evogene's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Evogene. We calculate exposure to Evogene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Evogene's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 5.8 M | 6.1 M | |
| Pretax Profit Margin | (2.12) | (2.23) | |
| Operating Profit Margin | (2.61) | (2.74) | |
| Net Loss | (1.94) | (2.03) | |
| Gross Profit Margin | 0.68 | 0.72 |
Evogene Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 5.7 M |
Evogene Current Valuation Indicators
Evogene's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Evogene's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Evogene, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Evogene's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Evogene's worth.When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.51) | Revenue Per Share | Quarterly Revenue Growth (0.42) | Return On Assets | Return On Equity |
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.